SEC Form 4 · accession 0001144204-15-071313
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mordechai Friedman
Director
Period of report
Dec 14, 2015
Accepted (ET)
Dec 16, 2015 · 5:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 14, 2015 | M | 5,000 | $0.75 | A | 5,000 | D | |
| Common StockF1 | Dec 14, 2015 | S | 5,000 | $2.57 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.75 | Dec 14, 2015 | M | 5,000 | D | — | Aug 15, 2024 | Common Stock | 5,000 | 11,666 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.56 to $2.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- F2The option, representing a right to purchase a total of 16,666 shares of common stock of the Issuer, became vested and exercisable in 12 consecutive, equal monthly installments commencing on September 15, 2014 and fully vested and exercisable on August 15, 2015.